Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and Behavior

Abstract Pathological aggregates of the microtubule-associated protein, tau, drive neuronal dysfunction in Alzheimer’s disease (AD) and related tauopathies. Yet, strategies to slow or eliminate progressive accumulation of misfolded tau protein in the brain remain underdeveloped relative to upstream therapeutic approaches, such as amyloid-beta (Aβ) immunotherapy. Here, we explore a coumarin-based series of brain-permeable small molecules that disaggregate tau. Structure–activity relationships (SAR) identified nitrile-containing analogs as potential leads from the series and suggest a stacking-driven disassembly mechanism. Small molecules from this series disaggregated tau from AD brain-derived matter, reducing aggregate burden measured in vitro across both fibrillar and oligomeric tau species, two principal pathological aggregate species implicated in disease. Mechanistic studies demonstrate that disaggregation does not generate soluble oligomeric intermediates, addressing a central question in the field. Inhibitor treatment reduces prion-like seeding, a disease-related mechanism by which tau aggregation pathology spreads in the brain. The lead candidate from this series is well tolerated in vivo, which enabled efficacy testing in a tauopathy mouse model. Treatment reduced tau pathology while preserving behavioral function, proteasome capacity, and synaptic integrity. These findings establish small-molecule tau disaggregation as a viable therapeutic strategy and provide a mechanistic framework for the design of aggregate-directed therapeutics in neurodegeneration.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-17
DOI
https://doi.org/10.1021/acsomega.6c08684
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and Behavior

Paul M. Seidler, Daniel Phillip Holschneider, Ian S. Haworth, Michael Walter Jakowec et al.
3 links
ACS Omega
Alzheimer's disease research and treatments
article

Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and Behavior

Paul M. Seidler, Daniel Phillip Holschneider, Ian S. Haworth, Michael Walter Jakowec, Giselle Maria Petzinger, 王金良, Ryan Patrick Foreman, Whitaker Cohn, Zhuo Wang, Zipeng Zheng, Rachel Khoury, Syed Kaleem Ahmed, Nader Mostowfi, Angela Albanese, Qiulan L. Ma, Qian Ma
article en

Abstract

Abstract Pathological aggregates of the microtubule-associated protein, tau, drive neuronal dysfunction in Alzheimer’s disease (AD) and related tauopathies. Yet, strategies to slow or eliminate progressive accumulation of misfolded tau protein in the brain remain underdeveloped relative to upstream therapeutic approaches, such as amyloid-beta (Aβ) immunotherapy. Here, we explore a coumarin-based series of brain-permeable small molecules that disaggregate tau. Structure–activity relationships (SAR) identified nitrile-containing analogs as potential leads from the series and suggest a stacking-driven disassembly mechanism. Small molecules from this series disaggregated tau from AD brain-derived matter, reducing aggregate burden measured in vitro across both fibrillar and oligomeric tau species, two principal pathological aggregate species implicated in disease. Mechanistic studies demonstrate that disaggregation does not generate soluble oligomeric intermediates, addressing a central question in the field. Inhibitor treatment reduces prion-like seeding, a disease-related mechanism by which tau aggregation pathology spreads in the brain. The lead candidate from this series is well tolerated in vivo, which enabled efficacy testing in a tauopathy mouse model. Treatment reduced tau pathology while preserving behavioral function, proteasome capacity, and synaptic integrity. These findings establish small-molecule tau disaggregation as a viable therapeutic strategy and provide a mechanistic framework for the design of aggregate-directed therapeutics in neurodegeneration.

ACS Omega
University of Southern California (US)
Pharmaron
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon